NR
BIO icon

Newfound Research’s Bio-Rad Laboratories Class A BIO Stock Holding History

Newfound Research’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-65
Closed -$34K – 131
2020
Q3 		$34K Buy
+65
New +$32.9K 0.1% 56

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Newfound Research's BIO Position: Q4 2020 in Review

Newfound Research sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 65 shares — an estimated $34K sold.

Newfound Research first reported a position in BIO in Q3 2020 and held it in 1 quarter. The position peaked at $34K in Q3 2020. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

  • Newfound Research reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
  • Newfound Research sold 65 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $34K.
  • Newfound Research first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 1 quarter.
  • Newfound Research's Bio-Rad Laboratories Class A position peaked at $34K in Q3 2020.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Newfound Research's 13F filing for Q4 2020, filed 22 Jan 2021.